Q3170833 (Q3170833): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Changed an Item: Edited by the materialized bot - inferring region from the coordinates)
(‎Created claim: summary (P836): Four out of five patients who refer after having had a first episode of schizophrenia will relapse in the next 5 years. The number of relapses and their duration is associated with a loss of brain integrity, worsening the prognosis of patients, compromising their psychosocial recovery and response to treatment, facilitating the development of a multi-episodic course and increasing economic costs. This reality underlines the importance of develop...)
Property / summary
 
Four out of five patients who refer after having had a first episode of schizophrenia will relapse in the next 5 years. The number of relapses and their duration is associated with a loss of brain integrity, worsening the prognosis of patients, compromising their psychosocial recovery and response to treatment, facilitating the development of a multi-episodic course and increasing economic costs. This reality underlines the importance of developing effective prevention of relapse into early stages of schizophrenia. This coordinating project aims to test the validity of a predictive model that predicts the risk of relapse in patients in remission after a first episode of schizophrenia, favoring the implementation in clinical guidelines and the National Health System of prevention measures that allow a more favorable evolution of this population. In order to make the results obtained in the two previous projects more efficient, we intend to validate techniques for the determination of levels of antipsychotics in blood and saliva of pharmacogenetics for the identification of biomarkers biological, neuroimage, physical health and cognition valid. After characterisation of the first episodes of schizophrenia and variables predicting the appearance of a second psychotic episode, the validation of these techniques would provide guidelines for clinical guidelines, based on the evidence, to define good clinical practice. (English)
Property / summary: Four out of five patients who refer after having had a first episode of schizophrenia will relapse in the next 5 years. The number of relapses and their duration is associated with a loss of brain integrity, worsening the prognosis of patients, compromising their psychosocial recovery and response to treatment, facilitating the development of a multi-episodic course and increasing economic costs. This reality underlines the importance of developing effective prevention of relapse into early stages of schizophrenia. This coordinating project aims to test the validity of a predictive model that predicts the risk of relapse in patients in remission after a first episode of schizophrenia, favoring the implementation in clinical guidelines and the National Health System of prevention measures that allow a more favorable evolution of this population. In order to make the results obtained in the two previous projects more efficient, we intend to validate techniques for the determination of levels of antipsychotics in blood and saliva of pharmacogenetics for the identification of biomarkers biological, neuroimage, physical health and cognition valid. After characterisation of the first episodes of schizophrenia and variables predicting the appearance of a second psychotic episode, the validation of these techniques would provide guidelines for clinical guidelines, based on the evidence, to define good clinical practice. (English) / rank
 
Normal rank
Property / summary: Four out of five patients who refer after having had a first episode of schizophrenia will relapse in the next 5 years. The number of relapses and their duration is associated with a loss of brain integrity, worsening the prognosis of patients, compromising their psychosocial recovery and response to treatment, facilitating the development of a multi-episodic course and increasing economic costs. This reality underlines the importance of developing effective prevention of relapse into early stages of schizophrenia. This coordinating project aims to test the validity of a predictive model that predicts the risk of relapse in patients in remission after a first episode of schizophrenia, favoring the implementation in clinical guidelines and the National Health System of prevention measures that allow a more favorable evolution of this population. In order to make the results obtained in the two previous projects more efficient, we intend to validate techniques for the determination of levels of antipsychotics in blood and saliva of pharmacogenetics for the identification of biomarkers biological, neuroimage, physical health and cognition valid. After characterisation of the first episodes of schizophrenia and variables predicting the appearance of a second psychotic episode, the validation of these techniques would provide guidelines for clinical guidelines, based on the evidence, to define good clinical practice. (English) / qualifier
 
point in time: 12 October 2021
Timestamp+2021-10-12T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0

Revision as of 18:03, 12 October 2021

Project Q3170833 in Spain
Language Label Description Also known as
English
No label defined
Project Q3170833 in Spain

    Statements

    0 references
    0 references
    43,500.0 Euro
    0 references
    87,000.0 Euro
    0 references
    50.0 percent
    0 references
    1 January 2015
    0 references
    31 March 2019
    0 references
    FUNDACION VASCA DE INNOVACION E INVESTIGACION SANITARIAS
    0 references

    42°50'47.44"N, 2°40'20.64"W
    0 references
    01059
    0 references
    Cuatro de cada cinco pacientes que remiten tras haber presentado un primer episodio de esquizofrenia sufrirán una recaída en los 5 años posteriores. El número de recaídas y su duración se asocia con una pérdida de la integridad cerebral, empeorando el pronóstico de los pacientes, comprometiendo su recuperación psicosocial y la respuesta al tratamiento, facilitando el desarrollo de un curso multiepisódico y aumentando los costes económicos. Esta realidad subraya la importancia de desarrollar una prevención efectiva de recaídas en los estadios tempranos de la esquizofrenia. El presente proyecto coordinando tiene como objetivo testar la validez de un modelo predictivo que predice el riesgo de presentar una recaída en pacientes en remisión tras un primer episodio de esquizofrenia, favoreciendo la implementación en las guías clínicas y al Sistema Nacional de Salud de medidas de prevención que permitan una evolución más favorable de esta población. Para hacer más eficientes los resultados obtenidos en los dos anteriores proyectos, se pretenden validar técnicas para la determinación de niveles de antipsicóticos en sangre y saliva de farmacogenética para la identificación de biomarcadores biológicos, de neuroimagen, de salud física y cognición válidos. Después de la caracterización de los primeros episodios de esquizofrenia y de variables que predicen la aparición de un segundo episodio psicótico, la validación de estas técnicas permitiría dar pautas para que las guías clínicas, basándose en la evidencia, definan una buena práctica clínica. (Spanish)
    0 references
    Four out of five patients who refer after having had a first episode of schizophrenia will relapse in the next 5 years. The number of relapses and their duration is associated with a loss of brain integrity, worsening the prognosis of patients, compromising their psychosocial recovery and response to treatment, facilitating the development of a multi-episodic course and increasing economic costs. This reality underlines the importance of developing effective prevention of relapse into early stages of schizophrenia. This coordinating project aims to test the validity of a predictive model that predicts the risk of relapse in patients in remission after a first episode of schizophrenia, favoring the implementation in clinical guidelines and the National Health System of prevention measures that allow a more favorable evolution of this population. In order to make the results obtained in the two previous projects more efficient, we intend to validate techniques for the determination of levels of antipsychotics in blood and saliva of pharmacogenetics for the identification of biomarkers biological, neuroimage, physical health and cognition valid. After characterisation of the first episodes of schizophrenia and variables predicting the appearance of a second psychotic episode, the validation of these techniques would provide guidelines for clinical guidelines, based on the evidence, to define good clinical practice. (English)
    12 October 2021
    0 references
    Vitoria-Gasteiz
    0 references

    Identifiers

    PI14_01900
    0 references